News

  1. South Carolina Oncology Associates, VitalSource(SM) Sign GPO Agreement 8/1/2011
    Cardinal Health today announced that South Carolina Oncology Associates, the largest community oncology practice in the state, has selected VitalSource(SM) as its group purchasing organization (GPO) for infused oncology and other specialty medications.
  2. Data Presented At American Association For Clinical Chemistry Meeting Show Many Americans May Have Low Vitamin D Levels 8/1/2011
    Data presented this week at the American Association for Clinical Chemistry (AACC) meeting showed that many people have low vitamin D levels and that testing individuals at risk may be beneficial.
  3. Penn Study Finds A Genetic Basis For Muscle Endurance In Animal Study 7/25/2011
    Researchers at the Perelman School of Medicine at the University of Pennsylvania have identified a gene for endurance, or more precisely, a negative regulator of it.
  4. Genethon And Children's Hospital Boston Get FDA Approval For A Wiskott Aldrich Gene Therapy Trial 7/22/2011
    The US Food & Drug Administration (FDA) approved the launching in the U.S. of a clinical trial for gene therapy for a rare immunodeficiency, Wiskott-Aldrich syndrome (WAS). After its implementation in Paris and London, this trial based on preclinical research performed at Genethon (Evry, France) which also manufactures the GMP gene therapy product, is now going to be launched in Boston.
  5. As HIV Treatment Improves, 'Trial Effect' Is Diminished, New Study Suggests 7/18/2011
    A new study by investigators from the University of North Carolina at Chapel Hill School of Medicine has confirmed the existence of a “trial effect” in clinical trials for treatment of HIV and also shows that effect has diminished over time.
  6. Comprehensive Clinical Performance Measurement, Reporting Solution Unveiled 7/8/2011
    To aid hospitals in complying with new and evolving regulatory reporting requirements while still prioritizing areas for overall improvement, Press Ganey has unveiled Quality Performer(SM).
  7. Data From Clinical Studies Of BioTheranostics' CancerTYPE ID® And Breast Cancer Index(SM) Molecular Diagnostic Tests Presented At ASCO 2011 Annual Meeting 6/7/2011
    bioTheranostics, Inc., a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID®, and Breast Cancer Index(SM).
  8. Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells As Potential Biomarker For Metastatic Prostate Cancer Clinical Trials 6/4/2011
    Data presented at the 47th American Society of Clinical Oncology (ASCO) annual meeting demonstrate the potential of circulating tumor cells (CTC) as a biomarker for metastatic prostate cancer clinical trials.